SCHEMBL542016

SCHEMBL542016

O=C(O)C/C=C(/CCC(=O)O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
EGLN1 Q9GZT9 3/20 0.45
ALKBH5 Q6P6C2 1/20 0.45
SUCNR1 Q9BXA5 1/20 0.45
MAPK1 P28482 1/20 0.42
SLC13A3 Q8WWT9 1/20 0.42
OR51E2 Q9H255 1/20 0.42
ALDH1A1 P00352 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
CPB1 P15086 1/20 0.38
SLC15A2 Q16348 1/20 0.36
KDM4E B2RXH2 2/20 0.36
TSHR P16473 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.35
KDM6B O15054 1/20 0.33
KDM5C P41229 1/20 0.33
FOLH1 Q04609 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542017 1.00 LMNA (0.45) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL10663575 0.95 EGLN1 (0.41) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL28327430 0.78 GRIK1 (0.48) LMNAEGLN1ALKBH5SUCNR1MAPK1
SCHEMBL17706757 0.78 AKR1B1 (0.43) LMNAOR51E2ALDH1A1ALOX15TSHR
SCHEMBL17706754 0.78 AKR1B1 (0.43) LMNAOR51E2ALDH1A1ALOX15TSHR
SCHEMBL17706761 0.78 AKR1B1 (0.43) LMNAOR51E2ALDH1A1ALOX15TSHR
SCHEMBL13541377 0.77 TSHR (0.54) ALDH1A1CYP2D6ALOX15CPB1KDM4E
SCHEMBL4887355 0.77 TSHR (0.54) ALDH1A1CYP2D6ALOX15CPB1KDM4E
SCHEMBL19407227 0.77 TSHR (0.54) ALDH1A1CYP2D6ALOX15CPB1KDM4E
SCHEMBL1897827 0.76 EGLN1 (0.41) LMNAEGLN1ALKBH5SUCNR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623962-B2 Olefin functionalization by metathesis reaction EXXONMOBIL CHEMICAL PATENTS INC. (US) 2014-01-07 US claimed
EP-1513794-B1 PREPARATION OF MONOMERS FOR GRAFTING TO POLYOLEFINS, AND LUBRICATING OIL COMPOSITIONS CONTAINING GRAFTED COPOLYMER CASTROL LTD (GB) 2013-03-06 EP claimed
US-20130030126-A1 Olefin Functionalization By Metathesis Reaction EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-01-31 US claimed
US-20120323018-A1 Preparation of Monomers for Grafting to Polyolefins, and Lubricating Oil Compositions Containing Grafted Copolymer GOLDBLATT IRWIN L (US) 2012-12-20 US claimed
US-8283419-B2 Olefin functionalization by metathesis reaction EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-10-09 US claimed
EP-2501726-A1 MULTIFUNCTIONAL MULTIPLE GRAFT MONOMER LOW MOLECULAR WEIGHT POLYMER Castrol Limited (GB) 2012-09-26 EP claimed
EP-2484660-A2 Preparation of monomers for grafting to polyolefins Castrol Limited (GB) 2012-08-08 EP claimed
US-20110287992-A1 MULTIFUNCTIONAL MULTIPLE GRAFT MONOMER LOW MOLECULAR WEIGHT POLYMER CASTROL LIMITED (US) 2011-11-24 US claimed
JP-2011525213-A 2011-09-15 JP claimed
US-7981847-B2 Dispersant viscosity index improvers comprising a polyolefin grafted with an unsaturated amide formed by the acylation of an amine by an unsaturated acid; raising the viscosity index of the base oil by at least about 5 points;keeping insoluble materials in the crankcase of an internal combustion engine CASTROL LIMITED (GB) 2011-07-19 US claimed
EP-1513794-A4 PREPARATION OF MONOMERS FOR GRAFTING TO POLYOLEFINS, AND LUBRICATING OIL COMPOSITIONS CONTAINING GRAFTED COPOLYMER CASTROL LTD (GB) 2008-09-10 EP claimed
US-20080139423-A1 Preparation of Monomers for Grafting to Polyolefins, and Lubricationg Oil Compositions Containing Graft Copolymer GOLDBLATT IRWIN L 2008-06-12 US claimed
US-7371713-B2 Preparation of monomers for grafting to polyolefins, and lubricating oil compositions containing grafted copolymer CASTROL LIMITED (GB) 2008-05-13 US claimed
EP-1874837-A1 MULTIPLE-FUNCTION DISPERSANT GRAFT POLYMER CASTROL LIMITED (GB) 2008-01-09 EP claimed
WO-2006116663-A1 MULTIPLE-FUNCTION DISPERSANT GRAFT POLYMER CASTROL LIMITED (GB) 2006-11-02 WO claimed
US-20050209113-A1 Preparation of functional monomers for grafting to low molecular weight polyalkenes and their use in the preparation of dispersants and lubricating oil compositions containing dispersant polyalkenes CASTROL LIMITED (GB) 2005-09-22 US claimed
EP-1533293-A2 Preparation of functional monomers for grafting to low molecular weight polyalkenes and their use in the preparation of dispersants and lubricating oil compositions containing dispersant polyalkenes CASTROL LIMITED (GB) 2005-05-25 EP claimed
EP-1513794-A2 PREPARATION OF MONOMERS FOR GRAFTING TO POLYOLEFINS, AND LUBRICATING OIL COMPOSITIONS CONTAINING GRAFTED COPOLYMER CASTROL LIMITED (GB) 2005-03-16 EP claimed
US-20040043909-A1 Preparation of monomers for grafting to polyolefins, and lubricating oil compositions containing grafted copolymer CASTROL LIMITED (GB) 2004-03-04 US claimed
WO-2003099890-A2 PREPARATION OF MONOMERS FOR GRAFTING TO POLYOLEFINS, AND LUBRICATING OIL COMPOSITIONS CONTAINING GRAFTED COPOLYMER CASTROL LIMITED (GB) 2003-12-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120323018-A1 Preparation of Monomers for Grafting to Polyolefins, and Lubricating Oil Compositions Containing Grafted Copolymer ALOX5, ACMSD, F12 LMNA 4024/4885EGLN1 2535/4885ALKBH5 171/4885
US-20130030126-A1 Olefin Functionalization By Metathesis Reaction MAX, AP1M1, AP3M1 LMNA 3077/4885EGLN1 4035/4885ALKBH5 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.